SANTA CLARA, Calif.– Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure (HF), today announced that Mark Miles has joined the company as Chief Commercial Officer (CCO). He will oversee commercialization strategy for the AccuCinch® Ventricular Restoration System, the only completely transcatheter procedure to treat the enlarged left ventricle for patients with symptomatic heart failure and a reduced ejection fraction (HFrEF), currently being evaluated in the CORCINCH-HF pivotal clinical trial.
“Mark’s track record in commercialization and marketing of groundbreaking medical device therapies adds an important dimension of expertise to the Ancora Heart team,” said Jeff Closs, president and CEO of Ancora Heart. “While we are currently focused on enrollment in our pivotal trial, we also recognize the importance of looking forward with an ultimate goal of transitioning from clinical to commercial-stage, and we are thrilled to have Mark on board to drive this strategy.”
A fundamentally different and innovative device-based therapy, the AccuCinch System is designed to improve the structure and function of the heart and help bring relief to patients with heart failure who remain symptomatic despite current guideline-directed medical care.
“I’m honored to be joining Ancora Heart as chief commercial officer, especially at this stage in the company’s development,” said Miles. “Ancora Heart’s innovative AccuCinch technology uniquely fills an important treatment gap for HFrEF patients, and I look forward to helping the Ancora Heart team establish a foundation for this tremendous opportunity in the continuum of heart failure care.”
Miles brings 25 years of experience scaling medical technology companies to Ancora Heart, including his most recent post as CCO of Terumo Aortic. In that role, he was responsible for global sales and marketing, custom solutions, portfolio strategy and expansion into new markets, helping guide the company during a period of significant growth.
Prior to his time at Terumo Aortic, Miles served as senior director of commercial strategy at Invuity, where he played a key role in driving adoption of their core product lines across key surgical specialties throughout the United States. He was instrumental in facilitating significant growth through the company’s eventual IPO in 2015. Previously, Miles held positions of increasing responsibility at Medtronic, serving as director of global marketing of the Endovascular Business Unit. He began his career at Eli Lilly and Company, serving various commercial leadership roles during his eight-year tenure. Miles received a Master of Business Administration from Pepperdine University and Bachelor of Science degree in health sciences from James Madison University.
